Brief: Cullinan Therapeutics Receives FDA Fast Track Designation For Cln-049

Cullinan Therapeutics

01/12/2025 12:59

Dec 1 (Reuters) - Cullinan Therapeutics Inc CGEM.O:

CULLINAN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR CLN-049, A NOVEL FLT3XCD3 T CELL ENGAGER, IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA

Source text: ID:nGNX4jFZNL

Further company coverage: CGEM.O

 ((Reuters.Briefs@thomsonreuters.com;))